‘Personalised medicine: a future vision’ at the upcoming 2019 FEBS Congress

Like Comment

The FEBS Science and Society Committee Special Session at the FEBS Congress this year in Krakow is focused on personalised medicine, also known as precision medicine.

The advance in the knowledge of the human genome and in the technology that allows it to be sequenced, analyzed and compared, is allowing the beginning of a new era in the study of human diseases – molecular biology is a major motor of transformation in the way diseases are studied and treated. Indeed, advances in understanding the molecular determinants of disease and of the response to treatments open new opportunities to develop tailor-made treatments and to use a wider array of drugs in those individuals who do not show specific adverse reactions. Precision medicine is essential for the diagnosis of rare diseases, which in turn offer an opportunity to understand basic mechanisms of common diseases. However, with the development of personalised medicine, individuals and health systems face new challenges, including balancing its risks and benefits while also considering its ethical, financial, social and legal implications, particularly regarding pricing and reimbursement, data protection and public interest in processing personal data.

Personalised medicine is special because it is a cross-cutting field that can only succeed if expertise and data from very different disciplines and sectors is brought together. A concerted effort is needed to make progress.

The aforementioned aspects will be presented and discussed in Krakow by three experts, as set out below. See you there!

FEBS Special Session on Science & Society – Personalised medicine: a future vision 

Tuesday July 9; 16:15–18:15; Organized by the FEBS Science and Society Committee

Chairs: Emmanouil Fragkoulis, Greece; Isabel Varela-Nieto, Spain
• Personalised lifestyle beyond personalised medicine: the future is here, Paolo Gasparini, Italy
• Bioethics and personalised medicine, Andrzej Kochanski, Poland
• Precision medicine of rare diseases and the link with common disorders, Francesc Palau, Spain

Top image: Pixabay.com

Isabel Varela Nieto

Research Professor, CSIC

Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates. She is currently the president of the SEBBM and a member of the FEBS Network working group and FEBS Science and Society Committee.